{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-041663","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.889926+00:00","generated_at":"2026-05-31T02:27:17.955071+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roivant sells Dermavant to Organon for up to $1.2B in cash plus royalties","bullets":["Total consideration up to ~$1.2B: $175M at closing, $75M milestone on FDA approval for atopic dermatitis, up to $950M in net sales milestones.","Tiered royalties: low-to-mid single-digit % on net sales up to $1B, 30% on net sales above $1B; all paid pro rata to Dermavant equity holders.","Roivant owns ~87% of Dermavant; merger expected to close Q4 2024, subject to HSR and antitrust conditions.","Organon will assume Dermavant's existing revenue interest purchase and funding agreements at closing.","Merger approved by Dermavant and Roivant boards and by shareholders holding at least 75% voting rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-041663","json":"https://secwatch.observer/filing/0001140361-24-041663.json","markdown":"https://secwatch.observer/filing/0001140361-24-041663.md","text":"https://secwatch.observer/filing/0001140361-24-041663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041663/0001140361-24-041663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041663/ny20036156x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:27:17.955071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}